Your session is about to expire
← Back to Search
Other
ADX-2191 for Retinitis Pigmentosa
Phase 2
Waitlist Available
Research Sponsored by Aldeyra Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial involves injecting ADX-2191 directly into the eyes of patients with retinitis pigmentosa caused by specific genetic mutations. The goal is to improve or stabilize their vision by addressing the genetic issue directly in the eye.
Eligible Conditions
- Retinitis Pigmentosa
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 16 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of participants with adverse events (AEs)
Secondary study objectives
Assessment for change in central subfield foveal thickness and ellipsoid zone area/width
Central retinal sensitivity
Change in dark-adapted retinal sensitivity
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: ADX-2191 Three InjectionsExperimental Treatment1 Intervention
Group II: ADX-2191 Six InjectionsExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ADX-2191
2022
Completed Phase 2
~10
Find a Location
Who is running the clinical trial?
Aldeyra Therapeutics, Inc.Lead Sponsor
32 Previous Clinical Trials
4,662 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger